November 9, 2010Circulation
OMEGA, a Randomized, Placebo-Controlled Trial to Test the Effect of Highly Purified Omega-3 Fatty Acids on Top of Modern Guideline-Adjusted Therapy After Myocardial Infarction
Why the study?
Does omega-3-acid ethyl esters-90 reduce the rate of sudden cardiac death in survivors of acute myocardial infarction receiving modern guideline-adjusted treatment?
Population
3,851 survivors of acute myocardial infarction randomized 3 to 14 days after acute MI across 104 German…
Comparison
Omega-3-acid ethyl esters-90 added to current… vs Placebo added to current guideline-adjusted…
Design
RCT, randomized, double-blind, placebo-controlled
Follow-up
365 days
Authors
Discussion
Loading...
Member takes
Implication
Does not support omega-3 use for sudden cardiac death prevention post-MI; confirms no benefit atop contemporary guideline-directed therapy.
Structured PICO
Does omega-3-acid ethyl esters-90 reduce the rate of sudden cardiac death in survivors of acute myocardial infarction receiving modern guideline-adjusted treatment?
P
Population
3,851 survivors of acute myocardial infarction (mean age 64.0 years, 25.6% female) randomized 3 to 14 days after acute MI across 104 German centers. 93.8% underwent acute coronary angiography and 77.8% acute percutaneous coronary intervention.
I
Intervention
Omega-3-acid ethyl esters-90 (1 g/d for 1 year) added to current guideline-adjusted treatment
C
Comparator
Placebo added to current guideline-adjusted treatment
O
Outcome
Rate of sudden cardiac death at 365 days follow-uphard clinical
Adding 1 g/d of highly purified omega-3 fatty acids to modern guideline-directed therapy after acute myocardial infarction does not reduce sudden cardiac death or other clinical events at 1 year.
Cite This Study
Rauch et al. (2010) studied this question.